Understanding JAK Inhibitors for Vitiligo: A New Era in Treatment

Categories:

Last updated: November 2026

What is Vitiligo?

Vitiligo is a skin condition that causes patches of skin to lose their color. It happens when the immune system attacks melanocytes, the cells that make skin pigment (melanin), leaving white or light patches. Vitiligo isn’t contagious or physically harmful, but it can have a deep emotional impact. Treatments have long included steroid creams and light therapy, and a newer group of medicines, JAK inhibitors, has changed what’s possible for many patients. Learn more about vitiligo treatment at Trillium Clinic.

What Are JAK Inhibitors?

JAK inhibitors (Janus kinase inhibitors) block enzymes called JAK1, JAK2, JAK3 and TYK2. These enzymes carry signals that drive inflammation and autoimmune attacks. Blocking them can calm the immune attack on melanocytes so pigment can return. They come as a cream applied to the skin or as pills taken by mouth.

How JAK Inhibitors Work in Vitiligo

In vitiligo, immune signals called cytokines travel through the JAK-STAT pathway and keep the attack on melanocytes going. JAK inhibitors interrupt that pathway. With the signal weakened, the attack slows, the spread of vitiligo can stop, and remaining melanocytes can start making pigment again.

JAK Inhibitors for Vitiligo: US Status at a Glance

MedicineFormStatus for vitiligo in the US
Opzelura (ruxolitinib)CreamFDA-approved (2022) for nonsegmental vitiligo, ages 12 and older
Rinvoq (upadacitinib)Pill, once a dayUnder FDA review; approved in the European Union in July 2026
Litfulo (ritlecitinib)Pill, once a dayPositive phase 3 results (July 2026); Pfizer plans to file for approval
PovorcitinibPillPositive phase 3 results (2026); Incyte plans to file in the first half of 2027
Olumiant (baricitinib)PillNot approved for vitiligo

Today, Opzelura cream is the only FDA-approved treatment for repigmentation in vitiligo in the US.

Types of JAK Inhibitors Used in Vitiligo Treatment

Opzelura (Ruxolitinib Cream)

Opzelura was approved by the FDA in July 2022 as the first treatment for repigmentation in nonsegmental vitiligo, for people 12 and older. It’s applied twice a day to no more than 10% of the body. In clinical trials, after 24 weeks about 30% of patients had 75% or more repigmentation on the face, and about 20% did on other parts of the body. It works less well on the hands and feet. Read more in our post on new vitiligo treatments and repigmentation.

Rinvoq (Upadacitinib) for Vitiligo

Rinvoq is a once-daily pill already FDA-approved for conditions such as atopic dermatitis and rheumatoid arthritis. For vitiligo:

  • Europe: in July 2026 the European Commission approved Rinvoq 15 mg for nonsegmental vitiligo in people 12 and older who are candidates for a pill or other whole-body treatment. It’s the first such medicine approved there.
  • United States: AbbVie submitted its FDA application in February 2026, and it is still under FDA review. Rinvoq is not yet FDA-approved for vitiligo.
  • Results (Viti-Up trials): at week 48, 28% to 33% of patients had 75% or more facial repigmentation, and 26% to 29% had at least half their total vitiligo area improve. Among patients who stayed on Rinvoq, those numbers kept rising through week 76, to 47% to 55% for the face and 40% to 43% for the whole body.

Olumiant (Baricitinib) for Vitiligo

Olumiant is a once-daily JAK pill. In the US it’s FDA-approved for adults with severe alopecia areata, some adults with rheumatoid arthritis and certain hospitalized COVID-19 patients. It is not approved for vitiligo.

Litfulo (Ritlecitinib) and Povorcitinib: In Development

  • Litfulo (ritlecitinib): already FDA-approved for severe alopecia areata in people 12 and older. In July 2026 Pfizer reported that two phase 3 vitiligo trials met their main goals for facial and total body repigmentation at week 52. Pfizer plans to file for approval for adults with nonsegmental vitiligo.
  • Povorcitinib: in two phase 3 trials in adults, about 19% of patients reached 75% or more facial repigmentation at week 52, compared with 3% to 7% on placebo. Incyte plans to file for approval in the first half of 2027.

Clinical Evidence Supporting JAK Inhibitors

The strongest evidence comes from large placebo-controlled trials:

  • Opzelura cream: about 30% of patients reached 75% or more facial repigmentation after 24 weeks.
  • Rinvoq pill: 28% to 33% reached 75% or more facial repigmentation at 48 weeks, rising to as high as 55% by 76 weeks in those who continued treatment.
  • Povorcitinib pill: about 19% reached 75% or more facial repigmentation at 52 weeks.

Repigmentation takes time: these trials measured results after 24 to 76 weeks of treatment. JAK inhibitors don’t work for everyone. Results depend on the type of vitiligo, how long patches have been present and where they are.

How JAK Inhibitors Are Used

  • Cream (Opzelura): applied twice a day to affected skin, best suited to limited areas such as the face.
  • Pills (such as Rinvoq where approved): taken once a day for more widespread or actively spreading vitiligo, with regular check-ups and blood tests.

A board-certified dermatologist can help you decide which approach fits your skin, age and health.

Potential Side Effects and Risks

Opzelura cream: the most common side effects in vitiligo trials were acne or itching where the cream was applied, cold symptoms, headache, urinary tract infection, redness and fever.

Boxed warning: all JAK inhibitors, including Opzelura cream, carry an FDA boxed warning for serious infections, higher risk of death, certain cancers, heart attack or stroke, and blood clots. These risks were mainly seen in adults 50 and older with heart risk factors who took a JAK pill for rheumatoid arthritis. In the Rinvoq vitiligo trials, high cholesterol was more common than with placebo.

Tell your dermatologist if you smoke or have had heart disease, a stroke, blood clots or cancer.

Combining JAK Inhibitors with Other Treatments

Narrowband UVB light therapy is a long-standing vitiligo treatment, and researchers are now testing it alongside JAK inhibitors. In a small AbbVie study of 84 adults, those who added twice-weekly narrowband UVB to Rinvoq had numerically higher repigmentation rates after 28 weeks than those on Rinvoq alone. Ask your dermatologist whether combining treatments makes sense for you. For an overview of light therapy, creams and other options, see advancing vitiligo treatments.

The Future of JAK Inhibitors in Vitiligo Treatment

The next few years could bring the first FDA-approved JAK pills for vitiligo. Rinvoq is under FDA review, Pfizer plans to file for Litfulo, and Incyte plans to file for povorcitinib in 2027. Long-term studies are also tracking how well results last and how safe these medicines are over time.

Final Thoughts

JAK inhibitors have opened up new options for vitiligo. In the US, Opzelura cream is approved now, and oral JAK inhibitors such as Rinvoq may follow. They aren’t a cure, but they can restore pigment and help stop vitiligo from spreading.

At Trillium Clinic, with offices in Chapel Hill, Smithfield and Burlington, North Carolina, a board-certified dermatologist can evaluate your vitiligo and talk through your options. Read our guide to vitiligo treatment options or schedule a consultation.

Frequently asked questions

Not yet in the US. Rinvoq (upadacitinib) was approved for nonsegmental vitiligo in the European Union in July 2026, for people 12 and older, and AbbVie's application is under FDA review. In the Viti-Up trials, up to 33% of patients had 75% or more facial repigmentation at 48 weeks.

No. Olumiant (baricitinib) is FDA-approved for adults with severe alopecia areata, some adults with rheumatoid arthritis and certain hospitalized COVID-19 patients, but not for vitiligo.

In the US, no JAK pill is FDA-approved for vitiligo yet. Rinvoq is under FDA review after its European approval, and Litfulo (ritlecitinib) and povorcitinib have had positive phase 3 vitiligo results with filings planned.

Opzelura (ruxolitinib) cream, approved in 2022 for nonsegmental vitiligo in people 12 and older. It's applied twice a day to no more than 10% of the body.

Repigmentation is gradual. Clinical trials measured results after 24 weeks for Opzelura and 48 to 76 weeks for Rinvoq, and results kept improving with longer treatment in the Rinvoq trials.

With Opzelura cream, the most common were acne or itching where it was applied, cold symptoms, headache and urinary tract infection. All JAK inhibitors carry an FDA boxed warning for serious infections, cancer, heart events and blood clots, so a dermatologist reviews your health history first.

About Dr. Weiss

Stefan C. Weiss, MD, FAAD, is a board-certified dermatologist, the medical director of Trillium Clinic and an adjunct professor of dermatology at Brown University. He trained at Duke University School of Medicine and Stanford University Medical Center, has authored more than 100 peer-reviewed abstracts, posters and manuscripts, and has over two decades of experience in medical and cosmetic dermatology.

References

  1. AbbVie. European Commission approval of Rinvoq for non-segmental vitiligo. July 2026.
  2. AbbVie. Long-term Rinvoq data showing continued repigmentation in non-segmental vitiligo. October 2026.
  3. Pfizer. Positive topline phase 3 results for Litfulo in nonsegmental vitiligo. July 2026.
  4. Incyte. First quarter 2026 results and business update (povorcitinib in vitiligo). April 2026.
  5. Incyte. Opzelura prescribing information.
  6. Incyte. Opzelura approval history. September 2025.
  7. American Academy of Dermatology. JAK inhibitors: what your dermatologist wants you to know.
  8. American Academy of Dermatology. Atopic dermatitis: diagnosis and treatment.
  9. U.S. Food and Drug Administration. JAK inhibitors: drug safety communication. 2021.

This article is for general education and isn’t a substitute for personal medical advice. A board-certified dermatologist can tell you which treatment is right for you.

About Us

Dr. Stefan C. Weiss, board-certified dermatologist at Trillium Clinic

Trillium Clinic Dermatology and Trillium Med Spa are dedicated to assisting patients embark on a transformative path toward improved wellness, radiant skin, and renewed confidence.

Have a Question?

Please reach out to us today…we look forward to hearing from you. Your path to radiant skin starts here.

Related Blogs

Trillium Clinic Logo